Who I met at the Bayer R&D DS&AI event in Madrid
Hi, I'm Lisa, the new R&D community engagement contact for DS&AI.
My name is Sandra Ille but I like to be called Sandy instead. I’ve been working for Bayer since November 2013 in the HR department. I’ve been an HRBP since I started and have always worked within the R&D organization since starting with Bayer. Currently I’m on a STA as a Global Talent Lead for the DS&AI organization. I reside in Bergenfield, NJ with my fiancé. I have a 24 year old son who is my greatest achievement and success. I have a BS and MS from West Virginia University.
I've met Wolfgang Thielemann at Bayer's DS&AI F2F Madrid
I am heading the Data Assets and Insights Solutions team focusing on creating impact on our pipeline with FAIRified, enriched, semantically integrated data products (e.g., Hubble) in combination with solutions which provide insights to key scientific and business questions along the entire R&D value chain (e.g. Aelixir).
The SCLM4Future project together with the PRINCE (Preclinical Information Center) project as well as the CONDAS (Connecting Data for Science) team is an excellent example for a successful cross-functional collaboration between CD&O, RED preMed and DS&AI within Research & Development but also between Platform IT and external partners. Together the team achieved to overcome legacy manual processes, redundant maintenance work, and functional silos by introducing new digital solutions and concepts with a strong collaborative mindset. The newly released SCLM 2.0 (Standard Codelist Maintenance) & PTO (Preclinical Terminology and Ontology) systems will enable our organization to improve the quality of controlled terminologies with regards to standard codelists and codes while reducing maintenance time and effort. This will have a positive impact on the code/codelist consistency across clinical and preclinical, as well as the compliance to regulatory requirements (e.g. CDISC (Clinical Data Interchange Standard Consortium) Controlled Terminology). The approach to share our knowledge as well as our efforts across functions will be an important step to archive our goals to increase data quality, interoperability and reusability – or to make a long story short: to make our data even more FAIR. For more information contact: Daniela Bergann.
I have met Seema Bhat at DS&AI Madrid, May 2023
I collaborate with different functions to acquire, process and transform data using technologies for better insights and decision-making for Pharma R&D.
I've met Miriam at Bayer's DS&AI Meeting in Madrid May 2023
I've met Miriam during a DS&AI meeting in May 2023 in Madrid. She works as a Data Steward within Data Strategy and Governance in the group Proprietary Information Management. She is a (computational) chemist by training and has particular experience with our chemical labjournal data.
Collaborations with external partners may lead to joint legal rights for compounds and data, which may restrict reusage in other projects. With the increasing number of collaborations at Bayer and with advancing time, memories of the project details fade, and reconstruction of the status will be nearly impossible. Therefore, we aim for a system to document the role of compounds, which will facilitate decisions on further usage in other collaborations. For more information contact: Miriam Wollenhaupt. Images taken from Microsoft Office free for use pictograms.
The Proprietary Information Management team, PIM, takes care of processes and systems related to either Compliance or Data Governance. Please talk to us if you need help with some cross-functional or collaboration-related topic or if you are interested to learn more about compound-related processes, compliance checks, lab notebook systems and similar things. For more information contact: Friederike Stoll.